Oncogenomics and the development of new cancer therapies

Robert L. Strausberg (), Andrew J.G. Simpson, Lloyd J. Old and Gregory J. Riggins
Additional contact information
Robert L. Strausberg: The Institute for Genomic Research, 9712 Medical Center Drive
Andrew J.G. Simpson: Ludwig Institute for Cancer Research
Lloyd J. Old: Ludwig Institute for Cancer Research
Gregory J. Riggins: Johns Hopkins University School of Medicine

Nature, 2004, vol. 429, issue 6990, 469-474

Abstract: Abstract Scientists have sequenced the human genome and identified most of its genes. Now it is time to use these genomic data, and the high-throughput technology developed to generate them, to tackle major health problems such as cancer. To accelerate our understanding of this disease and to produce targeted therapies, further basic mutational and functional genomic information is required. A systematic and coordinated approach, with the results freely available, should speed up progress. This will best be accomplished through an international academic and pharmaceutical oncogenomics initiative.

Date: 2004
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature02627 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:429:y:2004:i:6990:d:10.1038_nature02627

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature02627

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().